SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001123292-18-000519
Filing Date
2018-03-09
Accepted
2018-03-09 21:39:25
Documents
1
Period of Report
2018-02-27

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT edgar.html 3  
1 PRIMARY DOCUMENT edgar.xml 3 19257
  Complete submission text file 0001123292-18-000519.txt   20650
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Issuer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 3344 N. TORREY PINES ROAD SUITE 200 LA JOLLA CA 92037
Business Address
Moglia Stephen A. (Reporting) CIK: 0001665527 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33415 | Film No.: 18681758